Published in BMJ on May 02, 2012
Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A. Blood (2014) 0.78
Perioperative management of a patient with haemophilia-A for major abdominal surgery. Indian J Anaesth (2017) 0.75
Prophylaxis therapy in paediatric patients with haemophilia: a survey of clinical management trends in Italy. Blood Transfus (2015) 0.75
Facial and Scalp Swelling in the Pediatric Population With Hemophilia: A Diagnosis Pitfall. Eplasty (2016) 0.75
A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. Haematologica (2016) 0.75
Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA (2006) 4.75
Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med (2012) 3.05
Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med (2005) 1.82
The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood (2011) 1.67
High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke (2010) 1.64
High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood (2010) 1.61
Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood (2007) 1.60
Cardiovascular risk assessment in haemophilia patients. Thromb Haemost (2010) 1.57
Neurocognitive deficits in children with sickle cell disease: a comprehensive profile. Pediatr Blood Cancer (2010) 1.53
Acquired lysosomal storage caused by frequent plasmapheresis procedures with hydroxyethyl starch. Transfusion (2006) 1.50
PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2. Thromb Haemost (2008) 1.42
High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke (2006) 1.37
Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood (2012) 1.29
Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology (2006) 1.28
[Sickle cell disease in heel injection screening. II]. Ned Tijdschr Geneeskd (2009) 1.12
The natural course of hemodynamically stable pulmonary embolism: Clinical outcome and risk factors in a large prospective cohort study. Chest (2007) 1.12
Quality of life of female caregivers of children with sickle cell disease: a survey. Haematologica (2008) 1.11
Fibrinogen gamma' in ischemic stroke: a case-control study. Stroke (2008) 1.10
Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica (2006) 1.08
Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs (2002) 1.05
Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol (2009) 1.03
Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood (2004) 1.03
Haemostatic abnormalities in patients with liver disease. J Hepatol (2002) 1.02
Effect of genetic variations in syntaxin-binding protein-5 and syntaxin-2 on von Willebrand factor concentration and cardiovascular risk. Circ Cardiovasc Genet (2010) 1.01
Acute pulmonary embolism in childhood. Thromb Res (2005) 1.01
Neurocognitive deficits in children with sickle cell disease are associated with the severity of anemia. Pediatr Blood Cancer (2010) 1.00
Effects of ambient air pollution on hemostasis and inflammation. Environ Health Perspect (2009) 0.99
Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica (2007) 0.98
Variation in the von Willebrand factor gene is associated with von Willebrand factor levels and with the risk for cardiovascular disease. Blood (2010) 0.96
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood (2013) 0.96
Novel 112 kb (epsilonGgammaAgamma) deltabeta-thalassaemia deletion in a Dutch family. Br J Haematol (2003) 0.96
Paediatric anticoagulation guidelines. S Afr Med J (2012) 0.95
A review of hereditary and acquired coagulation disorders in the aetiology of ischaemic stroke. Int J Stroke (2010) 0.93
Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost (2010) 0.93
Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg (2007) 0.93
Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. Circ Cardiovasc Genet (2009) 0.92
Clinical practice: the bleeding child. Part II: disorders of secondary hemostasis and fibrinolysis. Eur J Pediatr (2011) 0.90
Circulating endothelial cells: a potential parameter of organ damage in sickle cell anemia? Blood Cells Mol Dis (2009) 0.90
Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost (2005) 0.90
Behavioral and emotional problems in children with sickle cell disease and healthy siblings: Multiple informants, multiple measures. Pediatr Blood Cancer (2009) 0.89
Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders. Clin Lymphoma Myeloma (2007) 0.88
Social participation of patients with hemophilia in the Netherlands. Blood (2007) 0.88
Identification of fibrin clot-bound plasma proteins. PLoS One (2012) 0.86
Effect of genetic variation in STXBP5 and STX2 on von Willebrand factor and bleeding phenotype in type 1 von Willebrand disease patients. PLoS One (2012) 0.85
Venous thromboembolic disease in childhood. Semin Thromb Hemost (2003) 0.85
The risk of postthrombotic syndrome in children with congenital heart disease. J Pediatr (2002) 0.84
Development and validation of a pediatric severity index for sickle cell patients. Am J Hematol (2010) 0.84
Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. Blood (2009) 0.84
Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Explanations and potential ameliorations. Thromb Haemost (2010) 0.84
Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol (2009) 0.84
Relationship of Von Willebrand Factor with carotid artery and aortic arch calcification in ischemic stroke patients. Atherosclerosis (2013) 0.84
Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res (2008) 0.83
Role of glycoprotein Ibalpha mobility in platelet function. Thromb Haemost (2010) 0.83
Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: similarities and differences. Arterioscler Thromb Vasc Biol (2011) 0.83
Mortality and causes of death in children with sickle cell disease in the Netherlands, before the introduction of neonatal screening. Br J Haematol (2011) 0.82
Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion. Eur J Haematol (2004) 0.82
Postvaricella purpura fulminans caused by acquired protein s deficiency resulting from antiprotein s antibodies: search for the epitopes. J Pediatr Hematol Oncol (2002) 0.82
Identifying children with sickle cell anaemia in a non-endemic country: age at diagnosis and presenting symptoms. Eur J Pediatr (2006) 0.81
Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome. Thromb Haemost (2010) 0.81
Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis. Thromb Haemost (2007) 0.81
Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation. Hepatology (2002) 0.81
Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost (2012) 0.81
Excluding pulmonary embolism without imaging tests--can our diagnostic algorithm be optimized? Thromb Haemost (2008) 0.81
High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease. Thromb Res (2010) 0.81
Providing genetic risk information to parents of newborns with sickle cell trait: role of the general practitioner in neonatal screening. Genet Test Mol Biomarkers (2011) 0.81
A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients. EuroIntervention (2013) 0.80
Prognostic markers in young patients with premature coronary heart disease. Atherosclerosis (2012) 0.80
Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands. Br J Haematol (2012) 0.80
Response to desmopressin is strongly dependent on F8 gene mutation type in mild and moderate haemophilia A. Thromb Haemost (2013) 0.80
Volume of white matter hyperintensities is an independent predictor of intelligence quotient and processing speed in children with sickle cell disease. Br J Haematol (2014) 0.80
Analysis of factor VIII inhibitors in a haemophilia A patient with an Arg593-->Cys mutation using phage display. Br J Haematol (2002) 0.79
Coronary artery calcification in hemophilia A: no evidence for a protective effect of factor VIII deficiency on atherosclerosis. Arterioscler Thromb Vasc Biol (2011) 0.79
Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic venous thrombosis. Thromb Haemost (2008) 0.79
The relevance of P2Y(12)-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: a clinical follow-up. Thromb Haemost (2011) 0.79
[Sickle cell disease in heel injection screening. I]. Ned Tijdschr Geneeskd (2009) 0.79
Codon 24 (TAT>TAG) and codon 32 (ATG>AGG) (Hb Rotterdam): two novel alpha2 gene mutations associated with mild alpha-thalassemia found in the same family after newborn screening. Hemoglobin (2010) 0.79
JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis? Hepatology (2006) 0.78
PLA1/A2 polymorphism of the platelet glycoprotein receptor IIb/IIIa in young patients with cryptogenic TIA or ischemic stroke. Thromb Res (2002) 0.78
Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review. Br J Haematol (2014) 0.78
Superimposed coagulopathic conditions in cirrhosis: infection and endogenous heparinoids, renal failure, and endothelial dysfunction. Clin Liver Dis (2009) 0.78
The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A. Thromb Haemost (2015) 0.77
Double disadvantage: a case control study on health-related quality of life in children with sickle cell disease. Health Qual Life Outcomes (2010) 0.77
The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention. Thromb Haemost (2011) 0.77
Proteomic analysis reveals that apolipoprotein A1 levels are decreased in patients with Budd-Chiari syndrome. J Hepatol (2011) 0.77
Active von Willebrand factor and the risk of stroke. Atherosclerosis (2009) 0.77
The bleeding child. Part I: primary hemostatic disorders. Eur J Pediatr (2011) 0.77
Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study. Br J Haematol (2004) 0.77
Markers of endothelial dysfunction differ between subphenotypes in children with sickle cell disease. Thromb Res (2013) 0.77
Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb Haemost (2003) 0.77
Implementation of laparoscopic splenectomy in children and the incidence of portal vein thrombosis diagnosed by ultrasonography. J Pediatr Surg (2013) 0.77
Variation in fibrinogen FGG and FGA genes and risk of stroke: the Rotterdam Study. Thromb Haemost (2008) 0.76
Clinically suspected acute recurrent pulmonary embolism: a diagnostic challenge. Thromb Haemost (2007) 0.76
Strongly increased levels of fibrinogen elastase degradation products in patients with ischemic stroke. Br J Haematol (2008) 0.76
What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke? Cerebrovasc Dis (2004) 0.76